483
Spectrum Pharmaceuticals, Inc.Spectrum Pharmaceuticals, Inc. – FDA 483, Feb 12, 2020
Record Details
An FDA inspection of Spectrum Pharmaceuticals Inc. in Irvine, CA, revealed that the firm failed to promptly bring noncompliant investigators into compliance during clinical studies SPI-GCF-301 and SPI-GCF-302. This included numerous protocol deviations, missed study procedures, and significant delays in completing electronic case report forms (eCRFs). This issue was a repeat observation from a previous inspection.
View Company Profile
ID · 3ae6deb6-ea4b-41f4-9fe6-c56a8fb1ece1
Other documents for Spectrum Pharmaceuticals, Inc.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.